التفاصيل البيبلوغرافية
| العنوان: |
Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era |
| المؤلفون: |
Wensink, G Emerens, Elferink, Marloes A G, May, Anne M, Mol, Linda, Hamers, Patricia A H, Bakker, Sandra D, Creemers, Geert-Jan, de Groot, Jan Willem B, de Klerk, Gerty J, Haberkorn, Brigitte C M, Haringhuizen, Annebeth W, Hoekstra, Ronald, Hunting, J Cornelis B, Kerver, Emile D, Mathijssen-van Stein, Danielle, Polée, Marco B, Pruijt, Johannes F M, Quarles van Ufford-Mannesse, Patricia, Radema, Sandra, Rietbroek, Ronald C, Simkens, Lieke H J, Tanis, Bea C, Ten Bokkel Huinink, Daan, Tjin-A-Ton, Manuel L R, Tromp-van Driel, Cathrien S, Troost, Monique M, van de Wouw, Agnes J, van den Berkmortel, Franchette W P J, van der Pas, Anke J M, van der Velden, Ankie M T, van Dijk, Marjan A, van Dodewaard-de Jong, Joyce M, van Druten, Edith B, van Voorthuizen, Theo, Jan Veldhuis, Gerrit, Verheul, Henk M W, Vestjens, Hanneke J H M J, Vincent, Jeroen, Kranenburg, Onno W, Punt, Cornelis J A, Vink, Geraldine R, Roodhart, Jeanine M L, Koopman, Miriam |
| المساهمون: |
Verpleegafdeling Medische Oncologie, Onderzoek Medische Oncologie, Cancer, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, MS Medische Oncologie |
| سنة النشر: |
2021 |
| مصطلحات موضوعية: |
Oncology, Cancer Research, Journal Article |
| الوصف: |
BACKGROUND: Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present survival data on a large, comprehensive cohort of dMMR mCRC patients, treated with or without systemic non-immunotherapy. METHODS: Two hundred and eighty-one dMMR mCRC patients (n = 54 from three prospective Phase 3 CAIRO trials; n = 227 from the Netherlands Cancer Registry). Overall survival was analysed from diagnosis of mCRC (OS), from initiation of first-line (OS1) and second-line (OS2) systemic treatment. Cox regression analysis examined prognostic factors. As comparison for OS 2746 MMR proficient mCRC patients were identified. RESULTS: Of 281 dMMR patients, 62% received first-line and 26% second-line treatment. Median OS was 16.0 months (13.8-19.6) with antitumour therapy and 2.5 months (1.8-3.5) in untreated patients. OS1 was 12.8 months (10.7-15.2) and OS2 6.2 months (5.4-8.9) in treated dMMR patients. Treated dMMR patients had a 7.6-month shorter median OS than pMMR patients. CONCLUSION: Available data from immunotherapy trials lack a control arm with standard systemic treatment. Given the poor outcome compared to the immunotherapy results, our data strongly suggest a survival benefit of immunotherapy in dMMR mCRC patients. |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| تدمد: |
0007-0920 |
| Relation: |
https://dspace.library.uu.nl/handle/1874/440861 |
| الاتاحة: |
https://dspace.library.uu.nl/handle/1874/440861 |
| Rights: |
info:eu-repo/semantics/ClosedAccess |
| رقم الانضمام: |
edsbas.E3870C0A |
| قاعدة البيانات: |
BASE |
Full Text Finder